AbstractPreviously, priming with replication-competent adenovirus-SIV multigenic vaccines and boosting with envelope subunits strongly protected 39% of rhesus macaques against rectal SIVmac251 challenge. To evaluate protection durability, eleven of the protected and two SIV-infected unimmunized macaques that controlled viremia were re-challenged rectally with SIVmac251. Strong protection was observed in 8/11 vaccinees, including two exhibiting <50 SIV RNA copies. Decreased viremia compared to naïve controls was observed in the other three. The SIV-infected unimmunized macaques modestly controlled viremia but exhibited CD4 counts ≤200, unlike the protected macaques. Durable protection was associated with significantly increased SIV-specific ...
We have shown that sequential replicating adenovirus type 5 host range mutant human immunodeficiency...
A recombinant adenovirus serotype 5 (rAd5) vector-based vaccine for HIV-1 has recently failed in a p...
A recombinant adenovirus serotype 5 (rAd5) vector-based vaccine for HIV-1 has recently failed in a p...
AbstractPreviously, priming with replication-competent adenovirus-SIV multigenic vaccines and boosti...
AbstractPreviously, replicating adenovirus type 5 host range (Ad5hr)-HIV/SIV recombinant priming in ...
We report on prime-boost vaccine regimens with two simian adenovirus (Ad) vectors (SAdV) or two huma...
Conventional HIV T cell vaccine strategies have not been successful in containing acute peak viremia...
AbstractWe investigated the immunogenicity and efficacy of a bimodal prime/boost vaccine regimen giv...
A prophylactic vaccine against human immunodeficiency virus (HIV) remains a top priority in biomedic...
AbstractThree Indian rhesus macaques, Ad-SIV primed/protein boosted and exposed twice to high-dose m...
A prophylactic vaccine against human immunodeficiency virus (HIV) remains a top priority in biomedic...
Approximately 50% of rhesus macaques (RMs) expressing the major histocompatibility complex class I (...
A therapeutic vaccine that induces lasting control of HIV infection could eliminate the need for lif...
AbstractRecent HIV vaccine failures have prompted calls for more preclinical vaccine testing in non-...
Producing a prophylactic vaccine for human immunodeficiency virus (HIV) has proven to be a challenge...
We have shown that sequential replicating adenovirus type 5 host range mutant human immunodeficiency...
A recombinant adenovirus serotype 5 (rAd5) vector-based vaccine for HIV-1 has recently failed in a p...
A recombinant adenovirus serotype 5 (rAd5) vector-based vaccine for HIV-1 has recently failed in a p...
AbstractPreviously, priming with replication-competent adenovirus-SIV multigenic vaccines and boosti...
AbstractPreviously, replicating adenovirus type 5 host range (Ad5hr)-HIV/SIV recombinant priming in ...
We report on prime-boost vaccine regimens with two simian adenovirus (Ad) vectors (SAdV) or two huma...
Conventional HIV T cell vaccine strategies have not been successful in containing acute peak viremia...
AbstractWe investigated the immunogenicity and efficacy of a bimodal prime/boost vaccine regimen giv...
A prophylactic vaccine against human immunodeficiency virus (HIV) remains a top priority in biomedic...
AbstractThree Indian rhesus macaques, Ad-SIV primed/protein boosted and exposed twice to high-dose m...
A prophylactic vaccine against human immunodeficiency virus (HIV) remains a top priority in biomedic...
Approximately 50% of rhesus macaques (RMs) expressing the major histocompatibility complex class I (...
A therapeutic vaccine that induces lasting control of HIV infection could eliminate the need for lif...
AbstractRecent HIV vaccine failures have prompted calls for more preclinical vaccine testing in non-...
Producing a prophylactic vaccine for human immunodeficiency virus (HIV) has proven to be a challenge...
We have shown that sequential replicating adenovirus type 5 host range mutant human immunodeficiency...
A recombinant adenovirus serotype 5 (rAd5) vector-based vaccine for HIV-1 has recently failed in a p...
A recombinant adenovirus serotype 5 (rAd5) vector-based vaccine for HIV-1 has recently failed in a p...